| [1] |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023 [J]. CA Cancer J Clin, 2023, 73(1): 17-48. DOI: 10.3322/caac.21763.
|
| [2] |
Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants [J]. Chin Med J (Engl), 2022， 135(5)：584-590. DOI: 10.1097/CM9.0000000000002108.
|
| [3] |
|
| [4] |
Santana Dos Santos E, Lallemand F, Petitalot A, et al. HRness in breast and ovarian cancers [J]. Int J Mol Sci， 2020, 21(11): 3850-3878. DOI: 10.3390/ijms21113850.
|
| [5] |
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA, 2017, 317(23): 2402-2416. DOI: 10.1001/jama.2017.7112.
|
| [6] |
Nakamura M, Obata T, Daikoku T, et al. The association and significance of p53 in gynecologic cancers: the potential of targeted therapy [J]. Int J Mol Sci, 2019, 20(21): 5482-5497. DOI: 10.3390/ijms20215482.
|
| [7] |
|
| [8] |
Enomoto T, Aoki D, Hattori K, et al. The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: characterizing the cross-sectionaL approach to ovarian cancer genetic testing of BRCA (Charlotte)[J]. Int J Gynecol Cancer， 2019, 29(6): 1043-1049. DOI: 10.1136/ijgc-2019-000384.
|
| [9] |
Hodgson DR, Dougherty BA, Lai Z, et al. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes [J]. Br J Cancer, 2018, 119(11): 1401-1409. DOI: 10.1038/s41416-018-0274-8.
|
| [10] |
Li VD, Li KH, Li JT. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from the cancer genome atlas and the international agency for research on cancer TP53 database [J]. J Cancer Res Clin Oncol, 2019, 145(3): 625-636. DOI: 10.1007/s00432-018-2817-z.
|
| [11] |
Klein SM, Bozko M, Toennießen A, et al. Determination of both TP53 mutation status and the amount of p53 protein has limited diagnostic importance for patients with ovarian cancer [J]. Curr Med Chem, 2022, 29(24): 4293-4300. DOI: 10.2174/0929867329666220112141211.
|
| [12] |
Bahena-González A, Toledo-Leyva A, Gallardo-Rincón D. PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies [J]. Chin Clin Oncol, 2020, 9(4): 51-62. DOI: 10.21037/cco-20-69.
|
| [13] |
|
| [14] |
Tew WP, Lacchetti C, Ellis A, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline [J]. J Clin Oncol, 2020, 38(30): 3468-3493. DOI: 10.1200/JCO.20.01924.
|
| [15] |
Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer [J]. N Engl J Med, 2018, 379(26): 2495-2505. DOI: 10.1056/NEJMoa1810858.
|
| [16] |
Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2017, 18(9): 1274-1284. DOI : 10.1016/S1470-2045(17)30469-2.
|
| [17] |
Wu XH, Zhu JQ, Yin RT, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial[J]. Ann Oncol, 2021, 32(4): 512-521. DOI: 10.1016/j.annonc.2020.12.018.
|
| [18] |
Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet, 2017, 390(10106): 1949-1961. DOI: 10.1016/S0140-6736(17)32440-6.
|
| [19] |
González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer [J]. N Engl J Med, 2019, 381(25): 2391-2402. DOI: 10.1056/NEJMoa1910962.
|
| [20] |
Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer [J]. N Engl J Med, 2019, 381(25): 2403-2415. DOI: 10.1056/NEJMoa1909707.
|
| [21] |
Ramraj SK, Elayapillai SP, Pelikan RC, et al. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53 [J]. Int J Cancer, 2020, 147(4): 1086-1097. DOI: 10.1002/ijc.32830.
|
| [22] |
Gourley C, Gabra H, Vergote I, et al. EUTROC PiSARRO: a phase Ⅰb study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC)[J]. J Clin Oncol, 2015， 33(15_suppl): 5605-5605. DOI: 10.1200/jco.2015.33.15_suppl.tps5605.
|
| [23] |
Murphy AD, Morgan RD, Clamp AR, et al. The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer [J]. Br J Cancer, 2022, 126(6): 851-864. DOI: 10.1038/s41416-021-01605-5.
|
| [24] |
|
| [25] |
Pignata S, Lorusso D, Joly F, et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial [J]. Lancet Oncol, 2021, 22(2): 267-276. DOI: 10.1016/S1470-2045(20)30637-9.
|
| [26] |
|
| [27] |
Arora S, Balasubramaniam S, Zhang H, et al. FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer[J]. Oncologist, 2021, 26(1): e164-e172. DOI: 10.1002/onco.13551.
|
| [28] |
Wieser V, Gaugg I, Fleischer M, et al. BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer [J]. Oncotarget, 2018, 9(25): 17501-17511. DOI: 10.18632/oncotarget.24770.
|
| [29] |
Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028 [J]. Gynecol Oncol, 2019, 152(2): 243-250. DOI: 10.1016/j.ygyno.2018.11.017.
|
| [30] |
Zhu J, Yan L, Wang Q. Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm Meta-analysis [J]. J Ovarian Res, 2021, 14(1): 112. DOI: 10.1186/s13048-021-00862-5.
|
| [31] |
Liu JF, Herold C, Gray KP, et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial [J]. JAMA Oncol, 2019, 5(12)：1731-1738. DOI : 10.1001/jamaoncol.2019.3343.
|
| [32] |
Gonzalez MA, Sanchez LL, Colombo N, et al. A phase Ⅲ，randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial [J]. Int J Gynecol Cancer, 2021, 31(4): 617-622. DOI: 10.1136/ijgc-2020-001633.
|
| [33] |
Monk BJ, Coleman RL, Fujiwara K, et al. Athena (GOG-3020/ENGOT-ov45): a randomized, phase Ⅲ trial to evaluate rucaparib as monotherapy (Athena-mono) and rucaparib in combination with nivolumab (Athena-combo) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer [J]. Int J Gynecol Cancer, 2021, 31(12): 1589-1594. DOI: 10.1136/ijgc-2021-002933.
|
| [34] |
|